Syngeneic peripheral blood stem cell transplantation with brief immunosuppression for severe aplastic anemia.

abstract：:Bone marrow transplantation recipients who were cytomegalovirus (CMV) seropositive and/or had a CMV seropositive donor were randomized for treatment with CMV hyperimmune plasma (n = 27) or no treatment at all (n = 27). The CMV hyperimmune plasma had neutralization titers greater than 250 and enzyme-linked immunosorben...

journal_title：Bone marrow transplantation

authors： Ringdén O,Pihlstedt P,Volin L,Nikoskelainen J,Lönnqvist B,Ruutu P,Ruutu T,Toivanen A,Wahren B

更新日期：1987-10-01 00:00:00

abstract：:Microangiopathic hemolytic anemia (MAHA) is a well-described complication of stem cell transplantation. Plasmapheresis is one modality utilized as therapy for patients who develop this complication. However, plasmapheresis may alter whole blood levels of certain medications and its effect on tacrolimus in bone marrow ...

journal_title：Bone marrow transplantation

authors： Hale GA,Reece DE,Munn RK,Kniska AB,Phillips GL

更新日期：2000-02-01 00:00:00

abstract：:Twenty three allogeneic bone marrow transplant (BMT) patients with female donors and 23 female autologous transplant patients were assessed for clonality status after transplant to determine the nature of haemopoietic reconstitution. The X chromosome probes PGK, HPRT and M27 beta were used to assess clonality by analy...

journal_title：Bone marrow transplantation

authors： Saunders MJ,Jowitt SN,Yin JA

更新日期：1995-01-01 00:00:00

abstract：:We investigated the proliferation and therapeutic utility of anti-CD3 activated splenocytes infused into mice following BMT. Using congenic mouse strains we demonstrated that splenocytes activated briefly ex vivo with anti-CD3 plus IL-2 (T-activated killer cells or T-AK) and infused intravenously following BMT had a g...

journal_title：Bone marrow transplantation

authors： Katsanis E,Xu Z,Anderson PM,Dancisak BB,Bausero MA,Weisdorf DJ,Blazar BR,Ochoa AC

更新日期：1994-10-01 00:00:00

abstract：:In 2005, the National Institutes of Health (NIH) chronic graft-versus-host disease (cGVHD) consensus project provided diagnosis and staging criteria, based mostly on clinical experience and expert opinion. These criteria were revised in 2014, aiming to provide enhanced specificity and clarity. However, the impact of 2...

journal_title：Bone marrow transplantation

authors： Kerep AZ,Broome J,Pirsl F,Curtis LM,Steinberg SM,Mitchell SA,Cowen EW,Pichard DC,Joe GO,Comis LE,Mays JW,Datiles MB 3rd,Stratton P,Zolton J,Berger A,Hendricks J,Kenyon M,Baruffaldi J,Titarenko I,Pulanic D,Baird K

更新日期：2019-01-01 00:00:00

abstract：:Myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue has been evaluated in the treatment of children and young adults with brain tumors for whom conventional therapy is either too toxic (for example, radiotherapy in infants) or ineffective (for example, recurrent malignant tumors). With this...

journal_title：Bone marrow transplantation

authors： Marachelian A,Butturini A,Finlay J

更新日期：2008-01-01 00:00:00

abstract：:Ten patients with Ph+ chronic myeloid leukemia (CML) were treated with idarubicin, cytarabine and etoposide followed by G-CSF to harvest Ph-negative progenitor cells. Six were in first chronic phase (CP1), and four beyond CP1. Between two and six aphereses (median 3, total 36) were performed starting 9-26 days (median...

journal_title：Bone marrow transplantation

authors： Mehta J,Mijović A,Powles R,Pagliuca A,Singhal S,Czepulkowski B,Swansbury GJ,Treleaven J,Mufti GJ

更新日期：1996-01-01 00:00:00

abstract：:Younger children are considered to be more vulnerable to late effects (LE), which prompted us to study LE in patients after haematopoietic stem cell transplantation (HSCT) for a haematological malignancy before the age of 3. In this multicentre EBMT study, cumulative incidence (CI) and severity of endocrine LE, centra...

journal_title：Bone marrow transplantation

authors： Bresters D,Lawitschka A,Cugno C,Pötschger U,Dalissier A,Michel G,Vettenranta K,Sundin M,Al-Seraihy A,Faraci M,Sedlacek P,Versluys AB,Jenkins A,Lutz P,Gibson B,Leiper A,Diaz MA,Shaw PJ,Skinner R,O'Brien TA,Salooja

更新日期：2016-11-01 00:00:00

abstract：:Sixty-nine adolescents and adults 15-51 years of age with untreated acute lymphoblastic leukaemia (ALL, 54 patients) or lymphoblastic lymphoma (LL, 15 patients) were referred for intensive antileukaemic therapy. Patients were treated according to one of two protocols. Both included induction and consolidation with vin...

journal_title：Bone marrow transplantation

authors： De Witte T,Awwad B,Boezeman J,Schattenberg A,Muus P,Raemaekers J,Preijers F,Strijckmans P,Haanen C

更新日期：1994-11-01 00:00:00

abstract：:This prospective pilot study aimed to evaluate the predictive value of (18)F-FDG PET/CT for early diagnosis of acute gastrointestinal GVHD (GI-GVHD). In all, 42 consecutive patients who received allo-SCT were included. (18)F-FDG PET/CT was systematically performed at a median of 28 (range, 24-38) days after allo-SCT. ...

journal_title：Bone marrow transplantation

authors： Bodet-Milin C,Lacombe M,Malard F,Lestang E,Cahu X,Chevallier P,Guillaume T,Delaunay J,Brissot E,Moreau P,Kraeber-Bodere F,Mohty M

更新日期：2014-01-01 00:00:00

abstract：:We evaluated the effect of individual and collective factors on the outcome of allogeneic haematopoietic stem cell transplantation (HSCT) at 35 French centres. Individual factors included patient and transplantation characteristics. Collective factors were related to the period and centre in which HSCT was performed. ...

journal_title：Bone marrow transplantation

authors： Mesnil F,Jouet JP,Tuppin P,Vernant JP,Golmard JL

更新日期：2004-10-01 00:00:00

abstract：:Rapid identification of a matched unrelated donor is essential for patients in need of hematopoietic SCT. We carried out a retrospective evaluation of 549 unrelated donor searches (UDSs), which were completed in 2005 for 23 German transplant centers. On the basis of the patient's HLA-DRB1 allele and DRB1-DQB1 haplotyp...

journal_title：Bone marrow transplantation

authors： Hirv K,Bloch K,Fischer M,Einsiedler B,Schrezenmeier H,Mytilineos J

更新日期：2009-10-01 00:00:00

abstract：:Thirty two allogeneic bone marrow transplant (BMT) recipients, aged 16-55 (median 35), with CMV antigenemia (= > 5 positive cells) developing at a median interval from BMT of 49 days, were given combined treatment with foscarnet and ganciclovir for 15 days. Maintenance was given with foscarnet and ganciclovir on alter...

journal_title：Bone marrow transplantation

authors： Bacigalupo A,Bregante S,Tedone E,Isaza A,Van Lint MT,Moro F,Trespi G,Occhini D,Gualandi F,Lamparelli T,Marmont AM

更新日期：1996-11-01 00:00:00

abstract：:The frequency of CTL precursors (CTLp) directed towards recipient-derived pre-transplant leukaemic blasts (LB) was measured in the peripheral blood of nine children with acute leukaemia and given BMT from either an HLA-identical sibling or a matched unrelated donor (MUD). Patients were evaluated at various time points...

journal_title：Bone marrow transplantation

authors： Montagna D,Locatelli F,Calcaterra V,Comoli P,Moretta A,Giorgiani G,Zecca M,Bonetti F,Giraldi E,Rondini G,Maccario R

更新日期：1998-10-01 00:00:00

abstract：:The remission state of 13 Philadelphia positive chronic myeloid leukemia patients was studied after bone marrow transplantation (BMT) by cytogenetic and Southern blot analysis of the breakpoint cluster region (BCR) gene. Eight of 13 patients showed neither clinical nor genetic evidence of residual disease. In two pati...

journal_title：Bone marrow transplantation

authors： Arnold R,Bartram CR,Heinze B,Carbonell F,Wiesneth M,Hertenstein B,Schmeiser T,Heit W,Kubanek B,Heimpel H

更新日期：1989-07-01 00:00:00

abstract：:We retrospectively studied a series of 23 patients (median age 50 years, range 29-59 years) with multiple myeloma (MM), treated in first relapse by a sequential autologous-allogeneic tandem approach. Tandem transplantation (TT) consisted in high dose melphalan (HDT) and auto-SCT followed by an (allo-SCT) preceded by t...

journal_title：Bone marrow transplantation

authors： Karlin L,Arnulf B,Chevret S,Ades L,Robin M,De Latour RP,Malphettes M,Kabbara N,Asli B,Rocha V,Fermand JP,Socie G

更新日期：2011-02-01 00:00:00

abstract：:The role of various cell subpopulations involved in the graft-versus-leukemia (GVL) effect induced by allogeneic bone marrow transplantation (BMT) was investigated in (BALB/c x C57BL/6)F1 (F1) recipients, inoculated with murine B cell leukemia (BCL1), by using monoclonal murine anti-IL-2 receptor antibodies or rabbit ...

journal_title：Bone marrow transplantation

authors： Weiss L,Reich S,Slavin S

更新日期：1995-09-01 00:00:00

abstract：:Prognostic factors for survival following allogeneic BMT for AML include age, disease status and cytogenetic risk classification. Lactate dehydrogenase (LDH) levels have not been studied as a potential risk factor. We reviewed our experience with BMT for AML and included LDH at the time of admission in an analysis of ...

journal_title：Bone marrow transplantation

authors： Kalaycio M,Rybicki L,Pohlman B,Dean R,Sweetenham J,Andresen S,Sobecks R,Sekeres MA,Advani A,Brown S,Bolwell B

更新日期：2007-10-01 00:00:00

abstract：:Superiority of single-donor apheresis platelets (SDAP) over pooled platelet concentrates (PPC) transfusions is largely assumed, but unproven. We hypothesized that prophylactic SDAP and PPC transfusions are clinically equivalent after allogeneic hematopoietic stem cell transplants (HSCT). We studied all transfusions ad...

journal_title：Bone marrow transplantation

authors： Gurkan E,Patah PA,Saliba RM,Ramos CA,Anderson BS,Champlin R,de Lima M,Lichtiger B

更新日期：2007-09-01 00:00:00

abstract：:We present 60 patients with refractory (n=8) or relapsed (n=52) adult ALL who received allogeneic hematopoietic SCT (HSCT) with (n=41) or without (n=19) prior reinduction chemotherapy. In our center, omission of reinduction is recommended if a suitable donor is promptly available, tumor burden is moderate and disease ...

journal_title：Bone marrow transplantation

authors： Terwey TH,Massenkeil G,Tamm I,Hemmati PG,Neuburger S,Martus P,Dörken B,Hoelzer D,Arnold R

更新日期：2008-12-01 00:00:00

abstract：:Considerable evidence in preclinical models as well as in human transplantation now suggests that donor-derived natural killer (NK) cells can contribute to alloimmune recognition of recipient residual tumour cells. This makes the NK cell population an attractive target for in vitro or in vivo manipulations, in order t...

journal_title：Bone marrow transplantation

authors： Lassailly F,Sielleur I,Blaise D,Chabannon C

更新日期：2005-01-01 00:00:00

abstract：:In the 1980s it became clear that low numbers of primitive hematopoietic cells were present in the peripheral bloodstream. Early clinical trials by investigators in the USA, Australia, and Germany demonstrated that these cells could be collected and reinfused to support high-dose chemotherapy procedures in patients ot...

journal_title：Bone marrow transplantation

authors： Shea TC

更新日期：1999-05-01 00:00:00

abstract：:CTLA-4 is a negative regulator of activated T cells and the association of CTLA-4 polymorphisms with autoimmune diseases and transplant outcome has been reported. We evaluated the effect of donor CTLA-4 polymorphisms on outcome after allogeneic hematopoietic SCT (HSCT). We analyzed 147 Japanese HLA-matched sibling rec...

journal_title：Bone marrow transplantation

authors： Murase M,Nishida T,Onizuka M,Inamoto Y,Sugimoto K,Imahashi N,Murata M,Miyamura K,Kodera Y,Inoko H,Naoe T

更新日期：2011-11-01 00:00:00

abstract：:Haematopoietic stem and progenitor cells (HSPC) mobilization, using cytokine-alone, is a well-tolerated regimen with predictable mobilization kinetics. Single-dose pegfilgrastim mobilizes HSPC efficiently; however, there is surprisingly little comparative data on its use without chemotherapy for HSPC mobilization. Peg...

journal_title：Bone marrow transplantation

authors： Herbert KE,Gambell P,Link EK,Mouminoglu A,Wall DM,Harrison SJ,Ritchie DS,Seymour JF,Prince HM

更新日期：2013-03-01 00:00:00

abstract：:Relapse of chronic lymphocytic leukemia (CLL) after allogeneic hematopoietic cell transplantation (HCT) remains a clinical challenge. We studied in a phase II trial whether the addition of peri-transplant rituximab would reduce the relapse risk compared with historical controls (n = 157). Patients (n = 55) received fl...

journal_title：Bone marrow transplantation

authors： Shadman M,Maloney DG,Storer B,Sandmaier BM,Chauncey TR,Smedegaard Andersen N,Niederwieser D,Shizuru J,Bruno B,Pulsipher MA,Maziarz RT,Agura ED,Hari P,Langston AA,Maris MB,McSweeney PA,Storb R,Sorror ML

更新日期：2020-01-01 00:00:00

abstract：:Over the past 15 years, SCT has emerged as a promising treatment option for patients with severe autoimmune diseases (ADs). Mechanistic studies recently provided the proof-of-concept that restoration of immunological tolerance can be achieved by haematopoietic SCT in chronic autoimmunity through eradication of the pat...

journal_title：Bone marrow transplantation

authors： Alexander T,Bondanza A,Muraro PA,Greco R,Saccardi R,Daikeler T,Kazmi M,Hawkey C,Simoes BP,Leblanc K,Fibbe WE,Moore J,Snarski E,Martin T,Hiepe F,Velardi A,Toubert A,Snowden JA,Farge D

更新日期：2015-02-01 00:00:00

abstract：:Data from autologous peripheral blood progenitor cell (PBPC) transplant recipients were used for cost analysis and modelling so as to link the main intervention procedures and clinical events to resource use and costs. This cohort consisted of 64 patients from 4 to 62 years old at transplantation (mean, 36.9 years) wh...

journal_title：Bone marrow transplantation

authors： Barosi G,Marchetti M,Alessandrino P,Locatelli F,Casula S,Lunghi M,Cazzola M,Giraldi E,Bernasconi C

更新日期：1999-04-01 00:00:00

abstract：:A nonmyeloablative conditioning regimen consisting of fludarabine (FLU) and 2 Gy TBI has been used extensively and with substantial engraftment success without promoting excessive nonrelapse mortality in medically infirm patients requiring hematopoietic cell transplantation. In this paper, we studied this same low-tox...

journal_title：Bone marrow transplantation

authors： Thakar MS,Kurre P,Storb R,Kletzel M,Frangoul H,Pulsipher MA,Leisenring W,Flowers ME,Sandmaier BM,Woolfrey A,Kiem HP

更新日期：2011-04-01 00:00:00

abstract：:We report the results of a retrospective single-center study comparing engraftment, acute and chronic GVHD, relapse and survival in patients with malignant hematological disorders transplanted with allogeneic peripheral blood stem cells (alloPBSCT, n = 40) or bone marrow cells (alloBMT, n = 42). All transplants were T...

journal_title：Bone marrow transplantation

authors： Barge RM,Brouwer RE,Beersma MF,Starrenburg CW,Zwinderman AH,Hale G,Waldmann H,den Ottolander GJ,Falkenburg JH,Willemze R,Fibbe WE

更新日期：2001-05-01 00:00:00

abstract：:From 1983 to 1994 two types of trials were performed. Between 1983 and 1987 a modified VAPA protocol (post-remission therapy with intensive sequential blocks for 12-16 months) was given to 40 patients from two institutions. CR was attained in 75% and 5-year EFS was 35%. In 1988 a post-remission protocol based on inten...

journal_title：Bone marrow transplantation

authors： Ortega JJ,Olivé T,Díaz de Heredia C,Coll MT,Bastida P,Massuet L

更新日期：1996-11-01 00:00:00